RxDoctor Payments Data

Lindsey White, MD

Cardiovascular Disease · Elizabeth City, NCNPI 1770535353

Payments from drug & device makers

$19,405in general payments, 2019–2025

Across 840 payments — averaging $23.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$8K
  • AstraZeneca$2K
  • Johnson & Johnson$2K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Novartis$948
  • E.r. Squibb & Sons, L.L.C.$924
  • plus $5K from 32 others

What the payments were for

  • Speaking & faculty fees$6,00031%
  • Food & beverage$13,18268%
  • Education$2231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,405 in reported general payments places this provider in the 75th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,008,950
Medicare patients
3,978
Services billed
17,486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,195$1,070,627
XareltoRivaroxaban561$472,493
EntrestoSacubitril/Valsartan379$402,501
FarxigaDapagliflozin Propanediol158$121,865
Repatha SureclickEvolocumab85$67,061
JanuviaSitagliptin Phosphate59$58,320
JardianceEmpagliflozin59$53,301
MultaqDronedarone Hcl19$23,470
Repatha SyringeEvolocumab15$18,995
VerquvoVericiguat27$16,967
Ranolazine ErRanolazine155$14,175
Praluent PenAlirocumab12$12,846
BrilintaTicagrelor17$12,505
Dofetilide44$10,372
DapagliflozinDapagliflozin Propanediol20$9,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$544$1,070,6271,195 claims
Johnson & JohnsonXarelto$1,541$472,493561 claims
NovartisEntresto$948$402,501379 claims
AstraZenecaFarxiga, Brilinta$1,584$134,370175 claims
MerckJanuvia, Verquvo$369$75,28786 claims
Boehringer IngelheimJardiance, Tradjenta$501$60,17172 claims
Sanofi-aventis U.S. LLCMultaq$234$23,47019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Elizabeth City

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →